↓ Expand ↓
  • Newscripts

    Fragrance Overload?

    [caption id="attachment_7452" align="alignleft" width="300" caption="Credit: Pascal Blachier via Wiki commons"][/caption] When humanity’s predilection for perfume meddles with the sense of smell of insects and animals, it can sometimes be fortuitous. Case in point: the discovery that Calvin Klein's Obsession perfume lures jaguars, tigers, and other big cats to expectant nature photographers and videographers. But meddling with odor receptors of other creatures can prove problematic. For example, the cosmetic and food fragrance 1-methylbutyl 3-methylbutanoate elicits aggressive defense behaviour in Continue reading →

  • The Haystack

    Orexigen Partners With Takeda for Potential Obesity Drug Contrave

    This morning Orexigen Therapeutics became the second of the three leaders in the obesity drug race to partner with a larger company. They've successfully courted Takeda, which now gets exclusive marketing rights to obesity drug Contrave in the U.S., Canada, and Mexico, if the drug gets regulatory approval. Orexigen's shares soared on the news, first released in the pre-dawn hours this morning. In the deal, Orexigen gets $50 million upfront from Takeda and could nab Continue reading →

  • The Chemical Notebook

    Industrial Gas Companies Face Brazilian Fine Muito Grande

    The Brazilian antitrust authority, Conselho Administrativo de Defesa Econômica (CADE), is levying fines totaling about $1.7 billion against Air Liquide, Air Products, Linde, Praxair’s Brazilian subsidiary White Martins. It has also implicated seven managers of those companies. CADE says it found evidence, through wire taps and searches, of an elaborate arrangement to divvy up the market by assigning customers to particular industrial gas companies. “CADE understands the actions of those companies that were investigated resulted Continue reading →

  • Cleantech Chemistry

    An Early Harvest of Biofuels News

    Here it is, the second day of September, and I've got a small pile of releases here about goings-on in the biofuels industry. Venture Capital maven and biofuels booster Vinod Khosla's Khosla Ventures is backing the first three companies in this roundup. [caption id="attachment_240" align="alignleft" width="150" caption="Renewable Crude by KiOR, Credit: KiOR"][/caption] First I need to go back in time a little bit (to Aug. 17) and commend Range Fuels on getting its commerical cellulosic Continue reading →

  • Terra Sigillata

    Physical exhaustion and scientific creativity

    I've just received the print version of The Chronicle of Higher Education and just have to share this with those of you who read our weekend post about being tormented by lab directors who aren't keen on non-science activities. In this front page article, "Running Jogs the Academic Mind," by Don Troop, several academicians hold forth on the value of physical activity, running in particular, as a means to trigger thinking about research problems. Religious Continue reading →

  • The Safety Zone

    Lab horror stories

    Care to share your favorite lab accident? There's a call out over at the chemistry reddit for your lab horror stories. An example: Two postdocs were working in the glovebox next to me. They spilled some MeLi and were mopping it up with kimwipes. They knew it would be dangerous when they pulled it out of the antechamber, so they prepared an EtOH bath (which, to be fair would safely neutralize a small amount of Continue reading →

  • Just Another Electron Pusher

    Profile: …cartoonist?

    The guy that I’m profiling for the blog today isn’t a chemist. At all. But he’s Jorge Cham, so does it matter? In case you’ve been living under something inorganic and heavy (or not a grad student), Cham is the creator of Piled Higher & Deeper, a comic strip about the...uniqueness... of  graduate student life. He gave his “Power of Procrastination” talk at ACS last week, and I managed to drag him into a quiet Continue reading →

The Haystack

» About This Blog

Orexigen Partners With Takeda for Potential Obesity Drug Contrave

This morning Orexigen Therapeutics became the second of the three leaders in the obesity drug race to partner with a larger company. They’ve successfully courted Takeda, which now gets exclusive marketing rights to obesity drug Contrave in the U.S., Canada, and Mexico, if the drug gets regulatory approval. Orexigen’s shares soared on the news, first released in the pre-dawn hours this morning.

In the deal, Orexigen gets $50 million upfront from Takeda and could nab up to $1 billion more, depending on whether Contrave meets certain regulatory and sales milestones. Further details about the agreement are available on an Orexigen press release.

Contrave refresher: Contrave is a combination of two drugs already on the market: naltrexone, which is typically used to manage alcohol or opioid dependence, and the antidepressant bupropion. Orexigen’s developed a sustained-release formulation of those active ingredients. This is thought to alleviate the nausea that cropped up in clinical trials, but also could come in handy in terms of real-world prescriptions if the drug is approved. People might want to save money by taking the generic versions of Contrave’s two components but it isn’t clear how that would work for them.

In July we covered the first partnership deal in the obesity drug race, that of Eisai and Arena Pharmaceuticals, which is developing the obesity drug candidate lorcaserin. It’s worth stepping back to compare and contrast the deals. Continue reading →



Bayer to Eliminate Unsightly Chin Fat

As my husband and I recently looked through photos of our wedding, he kept repeating the same thing: “Yikes, check out my triple chin.” Click. “Another triple chin.” Click. “Hmm, maybe I need to work out.”

In reality, his perceived folds of flab were a result of unfortunate camera angles (I swear, dear. Your chin is splendid.). But if a day comes when he genuinely suffers from chin bulge, Bayer might have just the solution. Yesterday, the company agreed to fork over $43 million upfront and upwards of $300 million in milestone payments for Kythera Biopharmaceuticals’ ATX-101, an adipolytic agent “designed to reduce small volumes of facial fat.” Yes, that’s right, folks: it’s a chin fat drug.

Because I tend to cover pharmaceuticals that are more in the disease-modifying category rather than those in the aesthetics-modifying category, I was pretty shocked by the price tag. Then I took a look at Allergan’s sales forecast for its wrinkle smoother Botox—the company is predicting it will bring in about $1.3 billion this year. (Well, that’s before subtracting out the $600 million Allergan agreed to pay today to settle criminal and civil charges related to the marketing of Botox.)

In other words, the potential market for ATX-101 seems pretty vast. Indeed, I imagine my husband isn’t the only one to look at a photo (poorly angled or not) and cringe. ATX-101 is in Phase II studies, and seems to be administrated in a relatively painless injection.

All this made me wonder how one goes about getting rid of small fat deposits without, well, sucking them out. It looks like the folks at Kythera, which is conveniently based in Los Angeles, first thought the active component in the formulation of ATX-101 was phosphatidylcholine, a major component of biological membranes that sports a polar head and fatty acid tails. However, further studies showed that deoxycholate, a secondary bile acid put into the formulation to make the phosphatidylcholine micelles soluble, was actually the secret to getting rid of unsightly chin fat. Deoxycholate, a detergent, causes a shift in the osmotic balance of a cell–in other words, water rushes into the fat cell, causing it to burst.  The finding was curious, as deoxycholate appeared to be only affecting fat tissues when administered in vivo. Kythera eventually determined that deoxycholate isn’t necessarily selective for fat cells, but that tissues in the subcutaneous fat that are protein rich are resistant to its effects. Hence, when administered locally, it appears to be able to get rid of the fat without impacting other tissues. And there you have it, drug goes in, fatty chin goes out. Since later stage trials are pending, the chin-fat sensitive will have to stick to photoshop for now.



An Invitation: Tell Us About Yourself

This post is the 100th we’ve written for The Haystack. So in celebration, we thought we’d try something a little different.

We’re here because we dig the chemistry and the business behind the pharmaceutical and biotech industries. But we know very little about why you’re here. And we’d like to be sure we’re giving you what you are looking for. So we’re asking for your help. It’s a plea that bloggers we admire (Ed Yong and many more) have put out many times before.

Tell us about you. Even (and especially) if you’ve never commented here before. Do you or have you ever worked for a pharma company or biotech? Do you have a scientific background? Maybe you’re more of a writer, investor, or businessperson. Feel free to say as much or as little as you like.

Tell us what you think of The Haystack. We’ve been blogging here for nearly 6 months, and that’s a good point to reflect on what we’re doing well and what we can do better. How did you find us, and if you’re a regular reader, what made you decide to stick around? What kinds of posts do you enjoy? What would you like to see less of?

Use the space in the comments to tell us what’s on your mind- the questions I’ve written are only a guide. Or for those not prone to public comment, feel free to email us (Lisa Lisa or CarmenCarmen) directly.



Sanofi Goes Public in Genzyme Bid

Sanofi-Aventis finally went public with its bid for Genzyme, and the biotech fired back with a press release noting its rejection of what it called an “opportunistic” bid that undervalues the company.

A little dateline to bring everyone who spent August laying on beaches up to speed on Sanofi’s courtship of Genzyme: Media reports of talks between Sanofi and Genzyme first surfaced on July 24. Sanofi’s CEO Chris Viehbacher sent over its “bear hug” offer (for those not in the financial world, a bear hug is a friendly bid that is well above the company’s recent share price) to Genzyme on July 29th. On August 11, Genzyme’s CEO Henri Termeer fired back a letter to Viehbacher rejecting the bid as “opportunistic.” Nevertheless, the companies’ financial advisors subsequently met on August 24, although Viehbacher said the meeting only reinforced Genzyme’s uncooperativeness. Yesterday, Sanofi put the pressure on by issuing a press release saying it had made its offer for Genzyme and this morning held a conference call with analysts to discuss the proposed transaction. Genzyme issued its own press release this morning calling the price tag “unrealistic” and undervaluing the company.

To review, Genzyme has been on a bit of a rollercoaster ride Continue reading →



From Pisces To Prodrugs: An Obesity Story

Sockeye salmon (Shutterstock)

When it comes to obesity, the drug race between Arena’s lorcaserin, Vivus’s Qnexa and Orexigen’s Contrave is at the forefront of folks’ minds these days.

But yesterday at the ACS National Meeting in Boston, I sat in on part of a session in the Division of Medicinal Chemistry that gave me a broad overview of other strategies for developing treatments for obesity. I heard a neat story from Donald L. Hertzog of GlaxoSmithKline that I thought I’d share.

GSK is focusing on the melanin concentrating hormone receptor protein as a target for obesity drugs. When I read the abstract, I thought I’d made a mistake. What in the world could the pigment melanin have to do with obesity?

It turns out there’s a fascinating connection. Continue reading →



Pharma Blogging Panel at ACS Boston

Welcome to the live coverage of the Chemical & Pharma Blogging panel. Yes, this pharma blog is live blogging the pharma blogging session. It’s very meta. On our panel today is Derek Lowe of In the Pipeline, Ed Silverman of Pharmalot, David Kroll of Terra Sigillata, and Mike Tarselli of Scripps Florida, and our moderater is none other than the Haystack’s Carmen Drahl.

12:08 A slight delay as the crowds descend upon the boxed lunches.

12:16 Derek Lowe is up first.

12:20: Derek started blogging in January or February of 2002. Though he worried at the time he wouldn’t have enough to write about– appears the supply of material is inexhaustable. It helps that he talks about business, IP, legal, science and he tries to rotate between those. It keeps the readership reasonably happy or at least equally unhappy. “I know if i I talk about IP for more than two posts, I can see the readership dropping.” It’s like spray repellant.

12:22 Derek gets about 15-20k pageviews per day. Big spike at lunchtime. Likes to think he has had a profound negative effect on productivity for the country. Readership seems to be a lot of chemists and people who work in the drug industry, but also a lot of folks outside the field.

12:24 Nabakov extensively quoted. Derek is literary, not just scientific!

12:25: A way to tell people where drugs really come from. Why do your prescriptions cost so much? Derek: “It’s me.”

12:26 Ed Silverman from Pharmalot is up next.

12:28 Ed comes at blogging from a different perspective: “I’m a journalist of all thing.” Started out on the pharma beat at the NJ Star-Ledger in 1995, and after ten years he proposed a blog. Got the greenlight in 2006–came up with the name “pharmalot,” with idea of covering what didn’t get covered in mainstream media. Started in Jan ’07.

12:30 Blogging has been an interesting experience–writing a blog has been one of the best career decisions he made. Keeps him in front of issues, meeting people, etc. Trying to cover a smattering of different things, and comes to pharma industry from a different perspective– as an outsider.

12:31 Ed also sees the crowd go quiet when he writes about patent stuff. Ah, the challenges of making IP enticing…

12:33 Now up, David Kroll of Terra Sigillata

12:35 A pharmacologist by training, but he does play well with chemists. He likes to think blogging serves bost chemistry and pharmacology. He grew up within sight of the Roche tower and always wanted to work for a pharma company. Life changed, and landed in academia.

12:37 Terra Sigillata is latin for “sealed earth”–It was the first trademarked medicine that came from a special clay. Abel Pharmboy (his pseudonym on the blog) comes from John Jacob Abel, the father of American pharmacology.

12:39 He came about blogging differently–growing up in NJ, always interested in mass communication and in teaching and conveying scientific knowledge to other folks. The greatest benefit of this medium is the ability to communicate science to non-scientists.

12:42 When he told people he was working on cancer, everyone was always interested and had questions. When regular folks felt like they had access to complex technical info, they seized upon it and got excited about it. “We tend to dumb down our communications too much.”

12:42 Derek Lowe was an inspiration for David’s blog. And felt like he really could perform a public service by talking about the risks and (few) benefits of herbal medicines. In 2006, was invited to join ScienceBlogs.com, which he says helped him develop breadth as a scientists by interacting with anthropologists, scientific ethicists, etc.

12:43 David left ScienceBlogs after PepsiGate of July 2010.

12:45 David’s joining C&ENtral Science! He will be moving to C&EN’s website–look for the first post up today! And he will be blogging under his real name.

12:48 David is talking about the many ways that blogging has benefited his career, his students, and more generally has enabled him to interact with a larger community.

12:49 Blogging has given him a chance to interact with a lot of communicators who have then come to the university to speak to students.

12:51 And blogging was written into one of his grants as a means of trying to make students more competitive for graduate school. Putting in a blogging mechanisms is helping students develop writing skills, particularly about science.

12:52 David’s top posts? Components of marijuana, horny goat weed, “stiff nights” (will leave it to the reader’s imagination to figure out what that herbal supplement is for). Even though his blog is dead on ScienceBlogs, it still gets about 900 hits a day from google searches.

12:54 Mike Tarsellis at Scripps Florida is up now. He’s talking about how he uses pharma/chem blogs.

12:55 Mike’s giving us his daily blog-reading schedule. In the Pipeline and Pharmalot are the morning coffee reads. Mid-morning? ACS Careers & Chemjobber (he’s a postdoc). Mid-afternoon? The Haystack (Aw…)

12:57 Mike did a survey of some fellow chemists, and most of them read them, but few trust the info. The idea was too many opinions, too few citations or too little verification.

12:58 Totally Synthetic most read among the scientists he works with–followed by the long-defunct (but much missed) Tenderbutton. When he asked them what they wanted out of a blog, they asked for more practical, hands-on info, more citations, yet also more gossip, and trouble-shooting advice. Most wanted: peer review discussion.

1:02 Some examples of crowd-sourced peer review that have or are having an impact on science. He’s talking about a controversial paper on biaryl formation by DMEDA organocatalysis–first post on this was by Derek on August 5. Has lead to a cadre of chemists all over the world repeating these reactions.

1:05 Q&A is now starting! Send your questions to me via twitter @lisamjarvis or in the comments to this post!

1:08 First question is basically whether you had a comfort with writing before starting a blog. Derek says he saw it as a strength of his that he thought he should try to put to use; David used to write for student newspapers before becoming a scientist; Ed was an accounting major in college, but loved literature; and Mike says he just likes to speak a lot.

1:14  A grad student asks about the potential pitfalls and how to navigate writing a blog as a grad student (her university wants her to write a blog). Derek talks about using his real name: he decided in the end it would come across as more trustworthy and it could only help to write under his real name. But blogging in grad school is a tough one because of relationship with professors, he notes. David thinks the university is forward thinking to want her to blog, and that it’s a great idea. The trick is to keep your experiences veiled enough, but it could be a tremendous opportunity to get away from the isolation many feel during PhD training. Ed talks about making the switch from working at a daily mainstream newspaper to blogging, which has some negative connotations. He’s dealt with that by being very transparent and by responding to comments without inserting himself into the conversation. Mike talks about tenderbutton, whose professor specifically asked him to stop blogging. Many advisors want you to be focused on work, and there can be a backlash as its seen as disrupting that.

1:16 What are the advantages of blog moderation? Derek takes down personal insults unless they’re interspersed with something interesting…David has only censored 2 comments in 5 years.

1:17 A question from chemjobber: How many non-reporter (i.e. non-professional journalist) blogs can the chem/pharma blogosphere support?

1:20 Ed tries to maintain civil order, and only inserts himself if there’s a question that needs answering.

1:22 Someone who recently finished his PhD thanks Derek for providing a forum for having insight info on what is going on inthe industry. He ended up at Genentech. Derek says he hopes that blogs can give grad students and post docs a look into what its really like because he had no idea what was going on in industry before he joined.

1:30 Finally going to get to chemjobber’s question!

1:34 Ed: Fewer than 1? The good blogs I look at are people who are already working regular jobs– they’re lawyers, they’re scientists, they’re professors, they’re not yet media moguls. Derek would agree: he hasn’t tried to turn his blog into a profession cause he’s always had drug discovery as his day job. Thinks he may e eating weeds out of his backyard if he tried to do that. David notes that you get $25/month per 10k pageviews on ScienceBlogs, which isn’t really going to support anyone. PZMeyers is probably the only one who can support himself that way.

1:37 A professor in the audience asks: when you sit down with a paper you want to write about, and you are aiming at a scientist (positively or negatively) rather than at a company, do you approach it differently? David notes that he just finished a five-year stint at NIH, so avoids anything related to that. And he tends to stick to positive papers. Derek will often write about a paper because he’s excited about it and thinks its neat stuff. But if he’s saying something nasty–which he does–he tries to put a disclaimer in there.

1:40 Mike: Academia is very compartamentalized, and one of the things blogs do for science is popularizes some things. If Derek puts up a paper, we are all deconstructing it by lunchtime, good or bad.

1:46 Someone asks who should get more attention? David suggests White Coat Underground while Ed thinks FDA Law Blog is good.

1:50 Carmen is wrapping things up and letting our illustrious panel off of the hot seat after two hours!



Aileron & Roche in Stapled Peptides Pact

Roche has agreed to pay up to $1.1 billion for access to technology at Aileron Therapeutics, a tiny Cambridge, Mass.-based biotech focused on developing stapled peptides. As part of the deal, Roche and Aileron will develop drug candidates against five targets.

Stapled peptides make intriguing drug candidates for their ability to access previously intractable targets. As we’ve described:

Protein-embedded α-helices mediate key protein handshakes in cancer, HIV, and other diseases. But actually using an α-helix as a drug has proven tricky. So-called stapled α-helices, boasting sturdy cross-links between nonnatural amino acid side chains, just might change that. This class of stabilized peptides can regulate signaling pathways to subvert cancer. They also appear to overcome several of the usual problems that have hampered the development of peptide drugs.

Stapled peptides are locked into the biologically active shape, enabling the drug to penetrate the cell and bind tightly to protein surfaces. Last fall, Harvard chemical biologist and Aileron’s scientific founder Gregory L. Verdine and colleagues showed the helix-stabilizing strategy could be used to turn off the Notch transcription factor complex, a master cell regulator in cancer that has gone awry in over half of patients with a certain type of leukemia. It was the first direct inhibitor of the Notch complex.

Aileron gets $25 million upfront and R&D funding, but could score a bounty in milestones if drug candidates against all five targets reach the market. Roche was clearly keeping close tabs on the technology. The Swiss pharma firm’s corporate venture fund was one of several big pharma funds to invest in the $40 million round raised by Aileron last summer.



First-time disclosure of Clinical Candidate live tweeting

UPDATED: Aug. 24- Structure of Pfizer drug is incorrect. Will re-post shortly.
2:01:27 PM: Hello, this is Leigh Krietsch Boerner live tweeting from the First-time Disclosure of Clinical Candidate session at #acs_bsoton #acsmedi

2:02:31 PM: First up is David Millan from Pfizer #acs_boston #acsmedi

2:04:11 PM: The name of the drug is PF-03715455

2:04:32 PM: The name of the drug is PF-03715455 #acs_boston #acsmedi

2:05:51 PM: It’s used to treat chronic obstructive pulmonary disease (COPD), which affects 30 million people worldwide #acs_boston #acsmedi

2:07:41 PM: It’s a p38 inhibitor, which is expressed and activated in the lungs of COPD patients #acs_boston #acsmedi

2:33:35 PM: Structure of Pf-03715455 #acs_boston #acsmedi

2:34:39 PM: Next up is Michael Sofia from Pharmasset, Inc. #acs_boston #acsmedi

2:35:29 PM: The name of the drugs are PSI-352938 and PSI-353661 #acs_boston #acsmedi

2:36:14 PM: It’s to treat Hepatitis C, or HCV, which affects 180 million people worldwide. #acs_boston #acsmedi

2:48:51 PM: The target is NS5B-RdRP, which is part of the RNA genome of the HCV virus #acs_boston #acsmedi

3:07:11 PM: Both drugs are 2′-alpha-F, 2′-beta-C-methyl nucleoside class #acs_bsoton, #acsmedi

3:09:44 PM: PSI-352938 is in phase 1b clinical trials, PSI-353661 entering phase 1 #acs_boston #acsmedi

3:10:18 PM: Next up is Dr. Orn Almarsson #acs_boston, #acsmedi

3:11:54 PM: He is from Alkermes, which is a biotechnology company #acs_boston #acsmedi

3:13:07 PM: They are working towards treatments for reward/impulse control disorders ie substance abuse, binge eating, etc #acs_boston #acsmedi

3:14:35 PM: Target is opiod modulation #acs_boston #acsmedi

3:16:05 PM: Will discuss ALKS 33 #acs_boston #scsmedi

3:27:26 PM: Attenuates dopamine release in the NAc shell stimulated by ethanol, AMPH and cocaine #acs_boston #acsmedi

3:27:55 PM: Range from phase 1 studies to phase 2/3 #acs_boston #acsmedi

3:31:52 PM: Phase 2/3 is in alcohol dependance adaptive trial. #acs_boston #acsmedi

3:32:55 PM: Partial kappa-opiod agonist, partial delta-opiod agonist/antagonist, potent mu-opiod antagonist #acs_boston #acsmedi

3:33:53 PM: Next talk is Vincent Mascitti, discovery of nes class of SGLT2 inhibitors, from Pfizer #acs_boston #acsmedi

3:34:34 PM: Phase 2, bridged ketal series, dioxa-bicyclo[3.2.1]octane motif #acs_boston #acsmedi

3:35:19 PM: SGLT2 is sodium glucose co-transporter 2 to treat type 2 diabetes #acs_boston #acsmedi

3:37:09 PM: for review of natural product synthesis, see Washburn, W.N. J Med Chem 2009 52, 1785 #acs_boston #acsmedi

3:50:59 PM: Another paper on these molecules is V. Mascitti & C. Prville Org Lett, 2010, 12 (13), pp 2940–2943 http://bit.ly/bvdHNS #acs_boston #acsmedi

3:59:59 PM: Last talk of the session is Paul Watson from Inspire Pharmaceuticals, Inc. #acs_boston #acsmedi

4:01:01 PM: The drug is INS115644 (latrunculin B) #acs_boston #acsmedi

4:01:36 PM: It’s to treat glaucoma, which is an optic neuropathy that can cause vision loss. #acs_boston #acsmedi

4:07:54 PM: Target inhibitors of actomyosin contractilily and inhibitors of microfilament assembly #acs_boston #acsmedi

4:10:30 PM: Naturally found latrunculin B is an actin plolymerication inhibitor, found in the red sea sponge #acs_boston #acsmedi

4:11:48 PM: That is actin polymerization inhibitor…#acs_boston #acsmedi

4:23:49 PM: Drug has gone through phase 1 clinical trials for proof of concept. #acs_boston #acsmedi

4:28:32 PM: That concludes the session.



Follow @LeighJKBoerner 8/22 For New Drug Info #acs_boston #acsmedi

Don’t forget- this Sunday, August 22, from 2PM to 4PM Eastern, Leigh Boerner (of Just Another Electron Pusher) will be tweeting from the ACS Meeting’s medicinal chemistry session on “First Time Disclosures of New Drug Candidates“.

In San Francisco, Paul Docherty of Totally Synthetic was kind enough to promote my tweets from this session. Time, unfortunately, got away from me this time around. So I neglected to ask him the favor again. Instead, I’m going the last-minute route and sending a trackback to his blog. If you’re visiting from TotSyn, welcome! And I hope you find information that’s useful to you here.

Follow Leigh on Twitter (@LeighJKBoerner) or here on The Haystack for updates on structures, targets, etc. I’m also adding Leigh’s tweets to my FriendFeed for viewing from there.



Has A Blog Entry Or Tweet Led To New Discoveries?

That’s an incredibly broad question I have up in my subject line, there. But it’s not my own. I’ve paraphrased one of the questions that folks have submitted at the survey I’ve set up so the chemblogging panel I’m moderating can get questions from folks who won’t be in Boston (or who wish to ask questions anonymously).

Here’s the exact question that was asked:

Are there any examples of blogging/tweeting that have directly lead to new discoveries or benefits to patients?

Chemjobber inspired me to give folks an early look at a couple of the questions I’ve been getting. I thought this question would be the perfect one to throw out there to the masses. While I’m sure Derek, Mike, David, and Ed will have ideas, I get the feeling readers will too.